Hence, among others, FcRn has emerged as a potential therapeutic target for AIBD (Ludwig, Kalies, Köhl, Zillikens, & Schmidt, 2013): In antibody transfer models of pemphigus, BP and EBA, lack of FcRn or β2 microglobulin expression conferred protection against disease development. Here, FCGRT is linked to acquired epidermolysis bullosa.